Equillium (NASDAQ:EQ) Second Quarter 2024 Results

Key Financial Results

• Revenue: US$13.9m (up 52% from 2Q 2023).

• Net income: US$468.0k (up from US$3.34m loss in 2Q 2023).

• Profit margin: 3.4% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue.

• EPS: US$0.013 (up from US$0.097 loss in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Equillium Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 119%. Earnings per share (EPS) also surpassed analyst estimates.

Looking ahead, revenue is expected to decline by 32% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the US are expected to grow by 23%.

Performance of the American Biotechs industry.

The company's shares are up 1.3% from a week ago.

Risk Analysis

Before you take the next step you should know about the 6 warning signs for Equillium (2 are significant!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.